1. Home
  2. IFRX vs UTMD Comparison

IFRX vs UTMD Comparison

Compare IFRX & UTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$1.31

Market Cap

225.5M

Sector

Health Care

ML Signal

N/A

Logo Utah Medical Products Inc.

UTMD

Utah Medical Products Inc.

N/A

Current Price

$70.84

Market Cap

216.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IFRX
UTMD
Founded
2007
1978
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
225.5M
216.1M
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
IFRX
UTMD
Price
$1.31
$70.84
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
★ $8.32
N/A
AVG Volume (30 Days)
★ 1.1M
32.2K
Earning Date
11-03-2026
10-22-2026
Dividend Yield
N/A
★ 1.77%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 1.66
Revenue
N/A
★ $38,520,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$43.63
Revenue Growth
★ N/A
N/A
52 Week Low
$0.80
$53.66
52 Week High
$2.95
$76.89

Technical Indicators

Market Signals
Indicator
IFRX
UTMD
Relative Strength Index (RSI) 31.05 45.55
Support Level $0.81 $67.40
Resistance Level $2.44 $72.81
Average True Range (ATR) 0.14 1.89
MACD -0.02 -0.18
Stochastic Oscillator 11.29 44.55

Price Performance

Historical Comparison
IFRX
UTMD

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About UTMD Utah Medical Products Inc.

Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.

Share on Social Networks: